Eli Lilly and Company $LLY Stock Purchased by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings increased its Eli Lilly stake by 5.7% in the third quarter, adding 2,507 shares to reach 46,657 shares valued at approximately $54 million. Institutional investors collectively own 82.53% of the company.
• Lilly’s growth outlook remains supported by weight-loss drug demand and major manufacturing investments. The company is building a $5 billion Virginia facility as part of a planned U.S. manufacturing expansion exceeding $50 billion, while analysts see continued opportunity for Mounjaro and Zepbound in emerging markets.
• Analyst sentiment is broadly positive, but valuation and near-term earnings pose risks. Lilly has a “Moderate Buy” consensus rating with an average price target of $1,317.93, while expectations for declining quarterly earnings and recent insider selling could weigh on sentiment.

Crossmark Global Holdings Inc. increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,657 shares of the company's stock after purchasing an additional 2,507 shares during the period. Eli Lilly and Company makes up 0.7% of Crossmark Global Holdings Inc.'s holdings, making the stock its 25th biggest holding. Crossmark Global Holdings Inc.'s holdings in Eli Lilly and Company were worth $53,986,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Maseco LLP increased its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $42,000. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $64,000. Finally, IMG Wealth Management Inc. boosted its stake in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock valued at $72,000 after buying an additional 50 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement
• Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook
• Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update
• Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article
• Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview
• Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 12th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. The Goldman Sachs Group restated a "buy" rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Finally, TD Cowen reaffirmed a "buy" rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $1,317.93.

Eli Lilly and Company Stock Down 2.4%

LLY stock opened at $1,275.50 on Friday. The stock's 50 day simple moving average is $1,186.64 and its 200 day simple moving average is $1,120.24. The company has a market cap of $1.20 trillion, a P/E ratio of 42.80, a price-to-earnings-growth ratio of 1.74 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.